GVS (GVS) investor relations material

Executive summary

• Q1 2026 revenue reached €105 million, up 3.9% at constant exchange rates, with adjusted EBITDA at €25.9 million (+0.3%) and a margin of 24.6%, improving by 57 basis points.

• Net income was €10.7 million (10.2% margin), while net profit including FX gains reached €11.4 million; net financial position stood at €249.8 million with leverage at 2.3x.

• Organic growth was 3.9%, driven by both volume (+2.4%) and pricing (+1.4%), despite a negative FX impact mainly from USD depreciation.

• The Group continued to invest in production facilities and automation, focusing on efficiency and flexibility.

Financial highlights

• Adjusted EBITDA margin improved by 57–60 basis points to 24.6%, mainly due to pricing and operational efficiency.

• Adjusted net income margin was 10.2%, with a slight decline year-over-year due to higher D&A from new plants and production transfers.

• Net financial position deteriorated by €9.7–10 million in Q1 due to working capital, but improved year-over-year after adjusting for extraordinary CapEx.

• Q1 2026 reported a €6.4 million adverse FX impact, primarily from EUR/USD depreciation.

• EBIT was €17.2 million, down from €18.8 million in Q1 2025.

Outlook and guidance

• FY 2026 guidance confirmed: low single-digit consolidated revenue growth at constant FX, with progressive acceleration expected.

• Adjusted EBITDA margin expected to expand by 20–50 basis points versus previous year; leverage ratio targeted at ~1.8x by year-end, excluding the impact of the voluntary partial tender offer.

• Working capital impact expected to be neutral by year-end, following typical seasonal trends.

• Medium-term plan update expected after summer.

• Strategic focus includes MedTech sub-division creation, Transfusion Medicine sales growth, Life Sciences customer validations, and Safety product ramp-up.